Discovery Laboratories has received a Phase 2 Small Business Innovation Research Grant (SBIR) from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for development of aerosolized KL4 surfactant for the treatment of lung damage caused by radiation. The initial award of $1 million can be supplemented by an … [Read more...] about Discovery Labs gets up to $3 million to develop KL4 aerosol for the treatment of radiation induced lung damage
News
Akorn acquires Sunovion’s Xopenex inhalation solution
Sunovion Pharmaceuticals has announced that it will sell "certain rights" to its Xopenex levalbuterol inhalation solution to Akorn for $45 million. Rights to the Xopenex HFA MDI are being retained by Sunovion. Akorn says that it will begin shipping the inhalation solution as soon as the deal is closed. Akorn CEO Raj Rai said, "We are excited to announce this … [Read more...] about Akorn acquires Sunovion’s Xopenex inhalation solution
Verona says RPL554 could treat cystic fibrosis
Verona Pharma says that the company will present data at the upcoming North American Cystic Fibrosis Conference showing that its RPL554 inhaled PDE3/PDE4 inhibitor could be useful in treating CF. According to the company, "The presentation, entitled 'CFTR activation by the dual phosphodiesterase 3/4 inhibitor RPL554 and the MRP4 inhibitor MK571,' reports data … [Read more...] about Verona says RPL554 could treat cystic fibrosis
Bespak parent company Consort Medical to acquire Aesica
Consort Medical, the parent company of device supplier Bespak, has announced that it will acquire CDMO Aesica Pharmaceuticals for £230 million, with the deal expected to be complete in November, 2014. Aesica offers development and manufacturing services for a range of OINDPs, including DPIs, inhalation solutions, and intranasal products. Aesica CEO Robert Hardy … [Read more...] about Bespak parent company Consort Medical to acquire Aesica
CHMP recommends approval of Duaklir Genuair inhaler
Almirall has announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company's aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. Almirall will market the product as Duaklir Genuair and Brimica Genuair in Europe. Almirall Chief Scientific Officer Thomas Eichholtz said, "We are very pleased … [Read more...] about CHMP recommends approval of Duaklir Genuair inhaler
Monash University to develop inhaled oxytocin in partnership with GSK
Monash University will license technology related to inhaled oxytocin for the treatment of postpartum hemorrhage to to GSK, the university and GSK have announced. Monash and GSK will collaborate on development through early clinical trials, including product optimization and manufacturing process development. Development of the dry powder formulation will be funded … [Read more...] about Monash University to develop inhaled oxytocin in partnership with GSK
FDA approval for Spiriva Respimat
According to Boehringer Ingelheim, the FDA has approved the company's Spiriva Respimat tiotropium bromide inhalation soft mist inhaler for the treatment of COPD. In August 2014, the FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted in favor of approval of the SMI. The company said that Spiriva Respimat should be available in January 2015. BI … [Read more...] about FDA approval for Spiriva Respimat
Invion announces completion of first feasibility studies for inhaled nadolol
According to Invion, the company has successfully completed the first stage of feasibility studies for its INV102 inhaled nadolol, which it intends to develop for the treatment of asthma, COPD, and cystic fibrosis. Invion is partnered with 3M Drug Delivery Systems for development of INV102 and INV104, inhaled zafirlukast. Nadolol is a beta blocker normally used … [Read more...] about Invion announces completion of first feasibility studies for inhaled nadolol
Civitas Therapeutics to be acquired by Acorda
Acorda Therapeutics has announced that it will acquire inhaled drug developer Civitas Therapeutics, including rights to the ARCUS inhalation platform, for $525 million in cash. The deal includes worldwide rights to Civitas's lead candidate, CVT-301 inhaled L-dopa for the treatment of OFF episodes in Parkinson’s disease patients. Civitas CEO Mark Iwicki said, “We … [Read more...] about Civitas Therapeutics to be acquired by Acorda
Dr. Reddy’s launches generic Xopenex inhalation solution in the US
Dr. Reddy’s Laboratories have announced that the company has launched generic levalbuterol inhalation solution in the US as of September 23, 2014. The generic version of Sunovion's Xopenex is available in 0.31 mg /3 mL, 0.63 mg /3 mL, and 1.25 mg / 3 mL unit dose vials. Read the Dr. Reddy's press release. … [Read more...] about Dr. Reddy’s launches generic Xopenex inhalation solution in the US